How I Diagnose Angioimmunoblastic T-Cell Lymphoma.
Xie Y, Jaffe ES.
Am J Clin Pathol. 2021 Jun 17;156(1):1-14. doi: 10.1093/ajcp/aqab090.
Advances in understanding of angioimmunoblastic T-cell lymphoma.
Chiba S, Sakata-Yanagimoto M.
Leukemia. 2020 Oct;34(10):2592-2606. doi: 10.1038/s41375-020-0990-y. Epub 2020 Jul 23.
Angioimmunoblastic T-cell lymphoma: the many-faced lymphoma.
Lunning MA, Vose JM.
Blood. 2017 Mar 2;129(9):1095-1102. doi: 10.1182/blood-2016-09-692541. Epub 2017 Jan 23.
Angioimmunoblastic lymphadenopathy: comprehensive review.
Levey IL.
Cancer Invest. 1987;5(6):633-47. doi: 10.3109/07357908709020323.
Angioimmunoblastic lymphadenopathy.
Su WP.
Dermatol Clin. 1985 Oct;3(4):759-68.
Angioimmunoblastic lymphadenopathy.
Emery P, Panayi GS.
Ann Rheum Dis. 1988 Jan;47(1):84. doi: 10.1136/ard.47.1.84-a.
Salazosulfapyridine-induced angioimmunoblastic lymphadenopathy.
Nakano A, Hatta K, Kobashi Y, Goto M, Imanaka T.
Intern Med. 1996 Nov;35(11):894-7. doi: 10.2169/internalmedicine.35.894.
Angioimmunoblastic lymphadenopathy with dysproteinemia: emphasis on pathogenesis and treatment.
Sallah S, Gagnon GA.
Acta Haematol. 1998;99(2):57-64. doi: 10.1159/000040811.
Angioimmunoblastic T-Cell Lymphoma.
Yabe M, Dogan A, Horwitz SM, Moskowitz AJ.
Cancer Treat Res. 2019;176:99-126. doi: 10.1007/978-3-319-99716-2_5.
Angioimmunoblastic lymphadenopathy with dysproteinemia.
Freter CE, Cossman J.
Semin Oncol. 1993 Dec;20(6):627-35.
